Bone Biologics Reports Q2 2026 Financial Results with Increased Net Loss and No Revenue

Bone Biologics Corporation has reported its financial results for the second quarter of 2026, revealing a net loss of $773,702, compared to a loss of $740,519 in the same period of the previous year. The company has not generated any revenue during this quarter, consistent with its ongoing focus on research and development. Total operating expenses for the quarter increased by 8% to $808,106, driven primarily by a 61% rise in research and development costs, which reached $308,747, as the company continues to invest in the development of its lead product, NELL-1/DBM. General and administrative expenses decreased by 10% to $499,359.

For the six months ending June 30, 2026, Bone Biologics reported a net loss of $1,539,690, a reduction of 12.4% from the $1,757,611 loss recorded in the same period in 2025. Total operating expenses for the first half of 2026 were $1,613,160, down 9.7% from $1,786,563 in the prior year. The decrease in research and development expenses, which fell to $450,344 from $615,186, was attributed to the timing of clinical trials. The company continues to anticipate significant investment in development activities as it prepares for pivotal clinical studies.

As of June 30, 2026, Bone Biologics had cash reserves of $4,031,780, a decrease from $5,334,322 at the end of 2025. The company has indicated that it will require additional financing to support its operations, with estimated operating expenditures for the next twelve months projected at $6.2 million. On July 7, 2026, Bone Biologics entered into a securities purchase agreement, raising approximately $2.7 million, which is expected to fund operations into the second quarter of 2027.

The company has also made strategic advancements, including the ongoing pilot clinical study of its NB1 bone graft device, which combines NELL-1 with demineralized bone matrix. This study is being conducted in Australia and aims to evaluate the safety and effectiveness of the device in treating degenerative disc disease. The study design has received FDA agreement, supporting the company's progression toward a pivotal clinical trial in the United States.

Looking ahead, Bone Biologics faces significant challenges, including the need for additional capital to sustain its operations and the successful completion of clinical trials. The company has expressed substantial doubt about its ability to continue as a going concern without securing further financing. The management remains focused on raising additional funds through debt or equity financing, although there are no assurances that such financing will be available on favorable terms.